Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) Latest Company News

Oct 29, 2026, 11:24 UTC
Zhongsheng Pharmaceutical reported first-three-quarter 2026 revenue of 1.468 billion yuan, down 22.28% year over year, and net profit attributable to shareholders of 177 million yuan, down 29.53%.
Source:
- finance.sina.cn
Oct 29, 2026, 11:24 UTC
Zhongsheng Pharmaceutical reported third-quarter 2026 revenue of 468 million yuan, down 20.62% year over year, and net profit attributable to shareholders of 65.157 million yuan, up 3.95%.
Source:
- finance.sina.cn
Oct 26, 2026, 09:14 UTC
China’s National Medical Products Administration approved a Phase III clinical trial of Zonsen Pharmaceutical’s ensitrelvir tablets for the additional indication of treating influenza A in patients at high risk of complications.
Source:
- finance.sina.cn
Oct 22, 2026, 09:36 UTC
China's National Medical Products Administration approved the registration of an arginine ibuprofen active pharmaceutical ingredient application submitted by Guangdong Xianqiang Pharmaceutical, a wholly owned subsidiary of Zhongsheng Pharmaceutical.
Source:
- finance.sina.cn
Oct 9, 2026, 09:33 UTC
China’s National Medical Products Administration approved cefixime granules for Guangdong Huanan Pharmaceutical Group, a wholly owned subsidiary of Zhongsheng Pharmaceutical, and issued a drug registration certificate.
Source:
- finance.sina.cn
Oct 8, 2026, 10:08 UTC
Zonsen Pharmaceutical’s subsidiary Zonsen Ruitron reported that its RAY1225 injection met the primary endpoint in a Phase III weight-loss trial, with the 9 mg group’s weight falling 22.24% from baseline after 52 weeks and 20.46% after placebo adjustment.
Source:
- finance.sina.cn
Oct 7, 2026, 07:50 UTC
China’s Center for Drug Evaluation included ZSP1601 tablets, developed by Zhongsheng Ruichuang, in its breakthrough therapy program for a proposed indication of MASH.
Source:
- finance.sina.cn
Sep 29, 2026, 08:42 UTC
Guangdong Zhongsheng Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its 0.05% emedastine difumarate eye drops, approved for marketing as a Class 4 chemical drug.
Source:
- finance.sina.cn
Sep 4, 2026, 09:44 UTC
Zhongsheng Pharmaceutical provided a joint liability guarantee of 200 million yuan for its wholly-owned subsidiary Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd. for a comprehensive credit line from Bank of Communications Dongguan Branch.
Source:
- finance.sina.cn
Sep 4, 2026, 09:44 UTC
Zhongsheng Pharmaceutical received approval from China's National Medical Products Administration to add a 0.2g specification of its fenofibrate capsules, deemed consistent with generic drug quality and efficacy.
Source:
- finance.sina.cn
Sep 2, 2026, 09:52 UTC
Zhongsheng Pharmaceutical's subsidiary Guangdong Zhongsheng Ruichuang Biotech received NMPA acceptance of its clinical trial application for a new indication of Anguradvir tablets to treat high-risk influenza A, planning a Phase III study.
Source:
- finance.sina.cn
Aug 17, 2026, 10:55 UTC
Zhongsheng Pharmaceutical announced on August 17, 2026 that it will acquire a 12.06% stake in its subsidiary Guangdong Zhongsheng Ruichuang Biotech from three shareholders for $28.2621 million, increasing its ownership from 77.12% to 89.18%.
Source:
- finance.sina.cn
Jul 31, 2026, 09:09 UTC
Zhongsheng Pharmaceutical's wholly-owned subsidiary Guangdong Xianqiang Pharmaceutical received approval from the National Medical Products Administration for the registration of its brexpiprazole API for market launch.
Source:
- finance.sina.cn

002317.SZ

Zhongsheng Pharmaceutical reported first-three-quarter 2026 revenue of 1.468 billion yuan, down 22.28% year over year, and net profit attributable to shareholders of 177 million yuan, down 29.53%.

Zhongsheng Pharmaceutical reported third-quarter 2026 revenue of 468 million yuan, down 20.62% year over year, and net profit attributable to shareholders of 65.157 million yuan, up 3.95%.

China’s National Medical Products Administration approved a Phase III clinical trial of Zonsen Pharmaceutical’s ensitrelvir tablets for the additional indication of treating influenza A in patients at high risk of complications.

China's National Medical Products Administration approved the registration of an arginine ibuprofen active pharmaceutical ingredient application submitted by Guangdong Xianqiang Pharmaceutical, a wholly owned subsidiary of Zhongsheng Pharmaceutical.

China’s National Medical Products Administration approved cefixime granules for Guangdong Huanan Pharmaceutical Group, a wholly owned subsidiary of Zhongsheng Pharmaceutical, and issued a drug registration certificate.

Zonsen Pharmaceutical’s subsidiary Zonsen Ruitron reported that its RAY1225 injection met the primary endpoint in a Phase III weight-loss trial, with the 9 mg group’s weight falling 22.24% from baseline after 52 weeks and 20.46% after placebo adjustment.

China’s Center for Drug Evaluation included ZSP1601 tablets, developed by Zhongsheng Ruichuang, in its breakthrough therapy program for a proposed indication of MASH.

Guangdong Zhongsheng Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its 0.05% emedastine difumarate eye drops, approved for marketing as a Class 4 chemical drug.

Zhongsheng Pharmaceutical provided a joint liability guarantee of 200 million yuan for its wholly-owned subsidiary Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd. for a comprehensive credit line from Bank of Communications Dongguan Branch.

Zhongsheng Pharmaceutical received approval from China's National Medical Products Administration to add a 0.2g specification of its fenofibrate capsules, deemed consistent with generic drug quality and efficacy.

Zhongsheng Pharmaceutical's subsidiary Guangdong Zhongsheng Ruichuang Biotech received NMPA acceptance of its clinical trial application for a new indication of Anguradvir tablets to treat high-risk influenza A, planning a Phase III study.

Zhongsheng Pharmaceutical announced on August 17, 2026 that it will acquire a 12.06% stake in its subsidiary Guangdong Zhongsheng Ruichuang Biotech from three shareholders for $28.2621 million, increasing its ownership from 77.12% to 89.18%.

Zhongsheng Pharmaceutical's wholly-owned subsidiary Guangdong Xianqiang Pharmaceutical received approval from the National Medical Products Administration for the registration of its brexpiprazole API for market launch.